What HAEMATO does

HAEMATO is a German pharmaceutical manufacturer and wholesaler founded in 1993, operating through its principal operating subsidiary HAEMATO PHARM GmbH from Schönefeld and Berlin-Bohnsdorf. The company runs two segments: (1) Specialty Pharmaceuticals, distributing more than 700 products across five therapeutic areas (HIV/AIDS, neurology, oncology, rheumatology, ophthalmology), including patent-protected medicines, biosimilars, generics, and — since 2019/2020 under a narcotics import and trade permit — cannabis products; and (2) Lifestyle & Aesthetics, which develops and distributes in-vitro diagnostic tests under the HAEMATO brand and cosmetics under the M1 SELECT brand via DTC channels. The business model is B2B pharmaceutical distribution at scale (over 7,000 pharmacy, wholesale, and clinic customers across Germany and Austria; 635,000 packages annually) with daily deliveries, next-day service if ordered by 6pm, and online ordering through the MSV3/Dafü system. Revenue is generated from product sales supplemented by discount agreements negotiated with statutory health insurance funds in Germany; pricing is not publicly disclosed. The Lifestyle & Aesthetics segment adds a consumer-revenue stream supported by social media (130,000+ Facebook, 100,000+ Instagram followers, 2.7M YouTube views) and a separate marketing infrastructure alongside educational materials commissioned by federal authorities within the marketing authorization framework.

The company employs approximately 60 full-time staff and operates from a combined 2,430 m² footprint. For 9M 2023, HAEMATO reported IFRS consolidated sales of EUR 212.2 million (up 13% year-over-year), EBITDA of EUR 10.2 million (up 33%), and EBIT of EUR 9.5 million (up 42%), with EUR 148.3 million of equity and an 80.3% equity ratio. Management subsequently raised full-year 2023 EBIT guidance to EUR 10-12 million. HAEMATO AG was historically listed on the Frankfurt Stock Exchange Basic Board (Open Market) under ISIN DE000A289VV1, but on November 30, 2023 the Management Board resolved to delist, effective after a three-month notice period ending February 2024, transitioning the group to a privately held structure.

Recent strategic actions include the November 15, 2023 termination of the proprietary botulinum toxin cooperation with Korean manufacturer Huons BioPharma following a profitability re-validation, and continued investment in the cannabis and biosimilars segments built on the 2019 narcotics license. The business carries no disclosed AI/ML capabilities or proprietary technology platform beyond distribution and manufacturing assets, with competitive positioning resting on regulatory permissions, therapeutic-area specialization, and last-mile specialty distribution scale.

Name

HAEMATO

Legal name

HAEMATO PHARM GmbH

Website

https://haemato.de

Company type

Public

Founded year

1993

Operating status

Operating

Short description

HAEMATO is a German pharmaceutical manufacturer and wholesaler distributing 700+ specialty products across HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology to 7,000+ pharmacies, wholesalers, and clinics in Germany and Austria, and operating a Lifestyle & Aesthetics segment with M1 SELECT cosmetics and HAEMATO diagnostic tests.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Specialty pharmaceuticals
• Pharmaceutical wholesale
• Biosimilars manufacturing
• Medical aesthetics products
• Cannabis pharmaceuticals

Headquarters

HQ city

Schönefeld

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical Wholesale: Sale of specialty pharmaceuticals including patent-protected medicines, biosimilars, generics, and narcotics/cannabis products to pharmacies, wholesalers, and clinics
2. Lifestyle & Aesthetics Products: Development and distribution of own brands including diagnostic tests and cosmetics (M1 SELECT), targeting health-conscious consumers and medical-aesthetic market

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

HAEMATO develops, manufactures and distributes specialty pharmaceuticals covering five therapeutic areas (HIV/AIDS, neurology, oncology, rheumatology, ophthalmology), including patent-protected medicines, biosimilars, generics, and narcotic/cannabis products. The company supplies pharmacies, wholesalers and clinics across Germany and Austria on a daily basis and also develops and distributes own brands in the Lifestyle & Aesthetics segment, notably M1 SELECT cosmetics and HAEMATO-branded diagnostic tests.

Product overview

HAEMATO is a pharmaceutical manufacturer and wholesaler operating two main divisions: Specialty Pharmaceuticals and Lifestyle & Aesthetics. The Specialty Pharmaceuticals division offers a specialized portfolio of over 700 products covering five therapeutic areas (HIV/AIDS, neurology, oncology, rheumatology, ophthalmology), including patent-protected medicines, generics, biosimilars, and narcotic pharmaceuticals with cannabis products. The Lifestyle & Aesthetics division develops, manufactures, and distributes own brands including diagnostic tests (HAEMATO brand) and cosmetics (M1 SELECT brand), along with third-party products. The company also provides discount agreements with health insurers and educational materials for drug safety.

Differentiator

Problem solved

Functional benefit

Brands

• M1 SELECT: Cosmetics brand for Lifestyle & Aesthetics segment
• HAEMATO (diagnostic tests)

Quantifiable outcome

• 13% sales growth in Q1-Q3 2023 to EUR 212.2 million
• +4 more outcomes

Named customers3 records

Segments2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Huons BioPharmaminorStrategic or Co-development Partner · 15 November 2023Previously partnered with Korean manufacturer Huons BioPharma on botulinum toxin project. However, this cooperation was terminated on November 15, 2023, due to new findings on changed market conditions and updated profitability validation. The project has been discontinued.

Scale indicators10 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• STADA Arzneimittel AG: German specialty and generic pharmaceutical manufacturer with a similar multi-therapeutic-area portfolio and biosimilar/generic strategy. Highly comparable in business model, European DACH focus, and mix of patent-protected plus off-patent pharmaceuticals.
• Dermapharm Holding SE: German specialty pharma manufacturer focused on niche therapeutic areas and own-brand products. Comparable to HAEMATO in its specialty positioning, German-market focus, and emphasis on selected high-margin therapeutic niches.
• Medios AG: Berlin-based specialty pharmaceutical distributor focused on high-priced medications for chronic and rare diseases in Germany. Closest direct peer in terms of specialty pharma distribution model, customer base (specialty pharmacies), and therapeutic-area focus.
• Biologische Heilmittel Heel GmbH: German biopharmaceutical manufacturer producing medicines from natural/biological sources. Comparable to HAEMATO's biopharmaceutical segment, German DACH focus, and own-brand pharmaceutical development approach.

Broad incumbents

• PHOENIX Group: Europe's largest pharmaceutical wholesaler with comprehensive distribution across Germany and other European markets. Comparable to HAEMATO's wholesale distribution backbone but operates at far greater scale and breadth.
• McKesson Europe (formerly Celesio/Lloyds Pharmacy): Major European pharmaceutical wholesaler and pharmacy operator. Comparable distribution infrastructure and customer base in Germany, though HAEMATO operates as a niche specialty distributor within McKesson's broader portfolio.
• Alliance Healthcare Germany (Walgreens Boots Alliance): German pharmaceutical wholesaler (formerly GEHE Pharma Handel) and pharmacy services provider. Overlaps with HAEMATO's pharmacy supply and wholesale distribution business in Germany.
• Bayer AG (Pharmaceuticals Division): Global pharmaceutical manufacturer with significant specialty pharma operations including oncology and women's health. Comparable as a broad incumbent in the German specialty pharma space, though at vastly greater scale and with proprietary R&D.

Regional players

• Redcare Pharmacy (formerly Shop Apotheke Europe): Netherlands-headquartered online pharmacy operating across Europe including Germany. Comparable to HAEMATO's Lifestyle & Aesthetics DTC/diagnostics channel in its German consumer-pharmacy reach.
• DocMorris (formerly Zur Rose Group): Swiss-headquartered online pharmacy with strong German presence. Overlaps with HAEMATO on the consumer-side pharmacy/diagnostics distribution and German-market focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/haemato.de
• Instagraminstagram.com/m1select
• LinkedInlinkedin.com/company/haemato

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAEMATO